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Abstract
Background: As other immimoassays, PTH determination is not free from interferences. Indeed, natural antibodies like heterophile antibodies (HAMA) and rheumatoid factor (RF) can induce falsely elevated results, leading to misdiagnosis and expensive unnecessary explorations. However, in routine practice, these interferences are not always obvious to detect.
Methods: On 2084 PTH samples, we applied a validation strategy in four steps to screen for HAMA and rheumatoid factor interferences. 
Results: 36% of our samples presented an elevated PTH. We found a clinically plausible reason for 91% of them. The remaining 63 suspicious samples were treated with HBT and 40% of them were found to be HAMA positive. RF determination was performed on the HAMA-negative samples and RF was positive in 21 of them. They were then treated with RF-Absorbent. Nine of these 21 samples presented RF interference. 
Conclusion: Applying this strategy in our routine validation, we managed to avoid spuriously elevated PTH results, which could have caused medical errors as well as unnecessary cost-effective extra-investigations.
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1. Introduction
Parathyroid hormone (PTH) is frequently measured in laboratories [1] with different automated methods to diagnostic and monitor hypoparathyroidism and primary or secondary hyperparathyroidism. It should be stressed that these methods need careful analytical and clinical validation, as well as a definition of specific reference interval before being used in clinical practice. We have thus evaluated the Liaison® N-tact PTH assay (Diasorin, Saluggia, Italy) [2], method routinely used in our laboratory.
As other immunoassays, PTH determination is not free from interferences. Indeed, natural antibodies like heterophile antibodies (HAMA) and rheumatoid factors (RF), which are auto-antibodies mainly of the IgM class binding preferably to IgG antibodies, can induce falsely elevated results, leading to misdiagnosis and expensive unnecessary explorations [3-5], However, in routine practice, these interferences are not always obvious to detect.
The aims of the present study were to evaluate the occurrence of these interferences on PTH determination with Diasorin Liaison (Saluggia, Italy) and to present a protocol for PTH validation, easily applicable in practice, which takes these interferences in consideration.
2. Material and methods
Liaison N-Tact PTH, a "second generation PTH assay", is a chemiluminescence immunoassay (CLIA) using a first antibody directed against the N-terminal (aa 1-34) region of the molecule conjugated to an isoluminol derivative and a second antibody directed against the C-terminal (aa 39-84) region immobilized on magnetic particles.
PTH results have to be interpreted together with serum 25-hydroxyvitamin D (25VTD), ionized calcium (Ca++) results and with the estimation of glomerular filtration (eGFR) rate by the MDRD equation [6]. We considered an elevated PTH (> 60 pg/ml, 6.30 pmol/l) result with normal 25 VTD (> 32 ng/ml, 80 nmol/l), normal Ca++ (comprised between 1.00 and 1.30 mmol/l) and eGFR > 60 ml/min/1.73 m2 as suspicious. Suspicious samples were treated, according to the manufacturer's instructions, with Heterophile Blocking Tubes (Scantibodies, Shantee, CA) to evaluate a possible interference with HAMA. As controls, 118 HAMA-negative patients were treated. We observed a recovery of 91.7%, a valuable result to consider HAMA treatment as acceptable, according to Ellis and Livesey [7].

Then, RF determination was performed on HAMA-negative samples on BNII (Siemens Diagnostics, ex-Dade Behring, Marburg, Germany). A sample was considered as RF-positive when the RF level detected was > 11 UI/ml.
RF-positive samples were treated with RF-Absorbent® (IBL, Hamburg, Germany), a reagent containing anti-human IgG antibodies to precipitate RF as follows: 400 µl of serum was added with 50 µl of RF-Absorbent, incubated 1 h at room temperature and analyzed in parallel with the non-treated serum.
Ten RF-negative samples containing a suspicious level of PTH were treated as controls. A sample presenting a drop in PTH level of 20% (twice the inter-assay of the test) after any treatment was considered as significantly influenced.
3. Results
We started to apply our validation criteria in May 2007. At the end of June, we had determined PTH for 2084 patients in our University laboratory. Amongst them, 743 presented an elevated level of PTH (36%). We found a plausible reason forthis result in 91% of the cases (54% of them were renal insufficient, 34% had a suboptimal level of 25VTD and 3% an abnormal calcium level). However, there were 63 patients for which the level of PTH could be considered as suspicious. After treatment of these sera with HBT tubes to search for HAMA interference, we observed a decrease of PTH in 25 of them (mean fall: 29%) and the level of 13 samples returned into normal range.
Amongst the 38 remaining patients with suspicious PTH which did not present HAMA interference, 21 were found to be positive for rheumatoid factor. PTH results obtained after RF-Absorbent treatment on these 21 samples, as well as RF values, are presented in Table 1. We observed a fall of more than 20% in PTH in 9 samples (43%) and the mean decrease in PTH levels observed in these samples was 46%. For 6 of them, PTH even returned into the normal laboratory ranges (Fig. 1).
There was no correlation between RF level and the difference in PTH observed after treatment.
In the control population, the mean PTH decrease was 5% and none of the 10 samples tested presented a fall of more than 20%.

Table 1 Results of PTH obtained in 21 RF-positive samples before and after treatment with RF-Absorbent®




























Fig. 1. Optimized strategy to eliminate interferences due to heterophile antibodies and rheumatoid factor in PTH determination.

4. Discussion
Immunoassays are very largely used throughout the world for the diagnostic or the follow-up of many diseases. Clinicians rely on those tests and are not necessarily aware of interferences, preanalytical [8] and analytical [9,10] problems that can lead to misdiagnosis or expensive complementary explorations [11,12], Natural antibodies are the major source of heterophile antibody interference [13] and many authors have shown rheumatoid factor interference in immunoassays [14-16], PTH determination on Liaison, as well as many other immunoassays, is not free from these interferences. In this study, we have shown that the serum of 34 of the 743 patients with an elevated PTH level presented in fact interference due to HAMA or RF (interference rate: 4.5%). Moreover, PTH of 18 of these patients returned into normal range after treatment. Nevertheless, one should keep in mind that even if the result observed after treatment was not back into the normal range, this does not mean that the patient has a pathologic PTH, as the interference hides the "true value". However, as it is not economically viable to test any positive PTH sample with HBT or RF-Absorbent, a strategy should be applied to validate PTH.
We have presented here a simple three step protocol, easy to apply in routine with new generation of laboratory information systems, which allowed us to screen for suspect PTH results. Firstly, we took into consideration 3 parameters, essential for a correct PTH clinical interpretation and that should be available at the time of validation: 25 OH-vitamin D, calcium levels and an estimation of the renal function. With these criteria, we found a plausible explanation for an elevation of PTH levels in 91% of our patients.
Then, suspect PTH values were confirmed by HBT treatment to remove the possible HAMA interference. We found that 40% of the 63 suspect samples were positive for HAMA.
Amongst the 38 HAMA-negative samples, we performed a rheumatoid factor determination. We found it to be positive in 55% of the cases. Finally, these 21 RF-positive samples were treated with RF-Absorbent®.
This strategy, tested on Liaison, could basically be applied to any PTH method. However, it should be noticed that RF-Absorbent treatment has to be validated in order to avoid matrix effects. Moreover, we cannot presume the percentages of interferences that might be observed with these other methods. Indeed, lack of standardisation and complexity of PTH determination [17] are closely related elements explaining, at least partially, these assay problems. Once again, one should also keep in mind that the validity of any treatment used to overcome interferences should be checked for each PTH determination kit [7].
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